It is proposed that there is somatic hypermutation of existing B cell clones rather than de novo generation from naive B cells in JN.1-adapted booster vaccines and this finding indicates maturation of pre-existing, class-switched MBC rather than substantial de novo recruitment of naïve B cells.
Abstract
The antigenic drift of SARS-CoV-2 toward the JN.1 lineage has prompted the development of variant-adapted COVID-19 booster vaccines. However, these boosters are thought to primarily recall pre-existing memory B cells (MBC), raising concerns about their ability to realign the immune response in highly pre-exposed populations. Here we analyze antibody and B cell responses in pre-exposed individuals (n = 42; median 4.5 prior COVID-19 vaccinations; 90% with at least one prior SARS-CoV-2 infection) following vaccination with a JN.1-adapted mRNA vaccine. Vaccination is associated with increased IgG binding and enhanced neutralization of JN.1 and related descendant variants. Longitudinal profiling of antigen-specific MBC shows that Wu01-only and Wu01/JN.1 cross-reactive cells remain dominant, while JN.1-only cells modestly increase by day 21. Single-cell RNA-sequencing of antigen-specific MBC in a representative sub-cohort (n = 7), combined with functional monoclonal antibody analyses, demonstrates that somatic hypermutation (SHM) drives intra-clonotype specialization toward improved JN.1 binding and neutralization. These findings indicate maturation of pre-existing, class-switched MBC rather than substantial de novo recruitment of naïve B cells. In conclusion, JN.1-adapted booster vaccination is associated with refinement of pre-existing MBC repertoires toward the JN.1 antigenic space and with enhanced neutralization of contemporary and antigenically proximate variants. Because of the continuous evolution of SARS-CoV-2, pre-existing immune responses may not be as effective against new viral variants. Here the authors investigate whether B cell responses to ancestral SARS-CoV-2 are stimulated by JN.1-adapted booster vaccines and propose that there is somatic hypermutation of existing B cell clones rather than de novo generation from naive B cells.
To investigate whether human donors with verified SARS-CoV-2 infection in early 2022, likely with Omicron (BA.1), generated variant-specific Bmem responses or whether WH1-reactive Bmem were preferentially boosted, a novel ImmunoSpot assay was established to assess cross-reactivity at single-cell resolution.
G. Kirchenbaum, Lingling Yao, N. Becza et al.· Journal of Immunology· 0 citations
Intranasal boosting promotes greater variant-specific response at both the serum and cellular levels than i.m.n. boosting, and ongoing B cell repertoire and mAb analyses will provide mechanistic insight into how vaccination route reshapes clonal selection and maturation, informing rational vaccination design.
Xinyi Liu, Chieh-Yu Liang, Michael S. Diamond· Journal of Immunology· 0 citations
Data indicate the KP.2 mRNA vaccine generates durable, cross-reactive responses against current Omicron subvariants, however, ongoing spike evolution impacts the neutralization of emerging lineages, highlighting the need for continued viral monitoring and timely vaccine updates.
Sanjeev Kumar, Li-Lin Lai, M. Ellis et al.· Journal of Virology· 0 citations
The observed waning of cross-neutralizing antibodies against emerging variants underscores the challenge of maintaining durable protection and supports the need for continued monitoring of antibody responses to guide evidence-based updates to COVID-19 vaccines.
Wei Wang, E. Goguet, Sabrina Lusvarghi et al.· Open Forum Infectious Diseas...· 0 citations
The dependence of effective variant-specific antibodies on vaccination history is shown which may explain birth-year influence on differential susceptibility to SARS-CoV-2 variants XFG and BA.3.3.2, and it is suggested that vaccination regimens in children should prioritize neutralization breadth.
T. Johnston, Rahul Subramanian, Wakinyan Benhamou et al.· bioRxiv· 0 citations
It is shown that a Wuhan-lineage-based multi-antigen VLP vaccine can provide cross-protection against an antigenically divergent SARS-CoV-2 variant that is not fully explained by detectable serum neutralizing activity alone, suggesting the importance of integrated immune responses involving humoral, cellular, and local...
Seung-Ji Kim, Howon Kim, Seung-Eun Son et al.· Vaccine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.